DECAF Score Calculator – COPD Exacerbation Mortality Risk
DECAF Score Assessment
Assess admission variables in adults hospitalized with an acute exacerbation of COPD.
Risk groups: 0–1 = low, 2 = intermediate, and 3–6 = high in-hospital mortality risk. These are risk strata, not an individualized mortality percentage.
About the DECAF Score
The DECAF (Dyspnoea, Eosinopenia, Consolidation, Acidaemia and atrial Fibrillation) score was developed to predict in-hospital mortality among adults admitted to hospital with an acute exacerbation of COPD.
The score ranges from 0 to 6. The extended MRC dyspnoea component contributes 0, 1 or 2 points; each of the remaining four components contributes 0 or 1 point.
Scoring criteria
| Variable | Criterion | Points |
|---|---|---|
| Dyspnoea | eMRCD 1–4 / 5a / 5b | 0 / 1 / 2 |
| Eosinopenia | Absolute eosinophils <0.05 × 10⁹/L | +1 |
| Consolidation | Consolidation on admission chest X-ray | +1 |
| Acidaemia | Admission arterial pH <7.30 | +1 |
| Atrial fibrillation | On ECG or known paroxysmal AF | +1 |
Risk interpretation
| DECAF score | Risk category | Outcome predicted |
|---|---|---|
| 0–1 | Low | Low in-hospital mortality risk |
| 2 | Intermediate | Intermediate in-hospital mortality risk |
| 3–6 | High | High in-hospital mortality risk |
Important scoring notes
- Assess eMRCD from the patient's usual state on a good day in the 3 months before the current exacerbation.
- eMRCD 5a means too breathless to leave home unaided but independent in washing and/or dressing. eMRCD 5b means housebound and dependent for washing and dressing.
- Eosinophil count is an absolute count, not a percentage.
- If ABG is not obtained, the validation study supports assigning 0 for acidaemia only when SpO₂ is >92% while breathing room air. Otherwise the pH component is unresolved.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.